Zealand Pharma's Share Count and Voting Rights Overview
Company announcement - No. 21 / 2025
Comprehensive Details on Shares and Voting Rights
Zealand Pharma A/S, a prominent player in the biotechnology sector, focuses on developing innovative peptide-based medications. As part of its transparency and compliance with the Danish Capital Markets Act, Zealand Pharma has provided updates regarding its share capital and voting rights as of the end of a recent month.
Amidst its ongoing growth and capital adjustments, Zealand Pharma announced a significant share capital increase following the exercise of employee warrants. This reflects the company's commitment to enhancing its capital structure and driving innovations in peptide medicines.
Key Financial Highlights
As per the latest data release, Zealand Pharma has reached a substantial milestone:
Total Shares: 71,364,728
This figure represents the nominal value of DKK 1 each. The share capital is also pegged at 71,364,728 DKK, aligning with the total number of shares. This highlights the company's robust capital base, which is pivotal for sustaining its research and development endeavors.
Voting Rights
Correspondingly, the total number of voting rights mirrors the number of shares, reaffirming a unified structure within the company. This attribute underscores the importance of shareholder engagement in the future direction of Zealand Pharma.
About Zealand Pharma A/S
Established in 1998 and headquartered in Copenhagen, Zealand Pharma A/S has made significant strides in the biotechnology field. Specializing in peptide-based therapeutics, the company has more than ten drug candidates advancing into clinical trials, with two already approved for market release. Their pipeline also includes three candidates that have reached late-stage development.
Zealand Pharma collaborates with various pharmaceutical companies, enhancing its reach and impact in the healthcare sector. This collaborative approach fosters innovation and supports the exploration of new therapeutic avenues, benefiting patients across the globe.
Presence and Expansion
With a solid presence in the United States alongside its Scandinavian roots, Zealand Pharma is well-positioned to navigate the global marketplace. The company’s strategic partnerships and alliances are crucial components in its pursuit of breakthroughs in peptide-based treatments, contributing to improved healthcare outcomes.
Contact Information for Investors
For those interested in learning more about Zealand Pharma's operations, the company has provided various contacts for inquiries:
Adam Lange
Vice President, Investor Relations
Contact: alange@zealandpharma.com
Neshat Ahmadi
Investor Relations Manager
Contact: neahmadi@zealandpharma.com
Rachel James-Owens
Vice President, Corporate Communications & Media Relations
Contact: RJamesOwens@zealandpharma.com
Frequently Asked Questions
What is the total number of shares for Zealand Pharma?
The total number of shares is 71,364,728, each with a nominal value of DKK 1.
How does the share count impact voting rights?
The number of voting rights equals the total number of shares, allowing shareholders to have a direct influence on company decisions.
What is Zealand Pharma's focus in the biotechnology field?
Zealand Pharma specializes in the discovery and development of peptide-based medicines, targeting various medical conditions.
When was Zealand Pharma founded?
Zealand Pharma was founded in 1998, establishing a footprint in the biotechnology industry.
How can investors contact Zealand Pharma for inquiries?
Investors can reach out to Adam Lange, Neshat Ahmadi, or Rachel James-Owens using the email addresses provided in this announcement.
